Evidence map›Paper›PMID 24048416›Full record

ArticleLeukemia2014

Molecular monitoring in NUP214-ABL-positive T-acute lymphoblastic leukemia reveals clonal diversity and helps to guide targeted therapy.

S Koschmieder, T Burmeister, M Brüggemann, A Berkemeier, S Volpert, P Wieacker, G Silling, N Gökbuget, C Müller-Tidow, W E Berdel and 1 more

Abstract readCase ReportsLetter
PubMed Publisher
In one paragraph

Article in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Case Report: The First Report ofFrontiers in oncology · 2021
    Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

S KoschmiederDepartment of Medicine A (Hematology and Oncology), University of Münster, Münster, Germany.
T BurmeisterCharité, CBF, Med. Klinik für Hämatologie, Onkologie und Tumorimmunologie, Hindenburgdamm 30, Berlin, Germany.
M BrüggemannSecond Medical Department, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
A BerkemeierDepartment of Medicine A (Hematology and Oncology), University of Münster, Münster, Germany.
S VolpertInstitute of Human Genetics, University of Münster, Münster, Germany.
P WieackerInstitute of Human Genetics, University of Münster, Münster, Germany.
G SillingDepartment of Medicine A (Hematology and Oncology), University of Münster, Münster, Germany.
N GökbugetDepartment of Hematology/Oncology, University Hospital Frankfurt, Frankfurt, Germany.
C Müller-TidowDepartment of Medicine A (Hematology and Oncology), University of Münster, Münster, Germany.
W E BerdelDepartment of Medicine A (Hematology and Oncology), University of Münster, Münster, Germany.
M StelljesDepartment of Medicine A (Hematology and Oncology), University of Münster, Münster, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsFatal OutcomeHematopoietic Stem Cell TransplantationHumansMaleMutationOncogene Proteins, FusionPrecursor T-Cell Lymphoblastic Leukemia-LymphomaTransplantation, HomologousYoung AdultNUP214-ABL1 fusion protein, humanOncogene Proteins, Fusion

Identifiers

PMID24048416

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.